A citation-based method for searching scientific literature

Sandra V Navarra, Renato M Guzmán, Alberto E Gallacher, Stephen Hall, Roger A Levy, Renato E Jimenez, Edmund K-M Li, Mathew Thomas, Ho-Youn Kim, Manuel G León, Coman Tanasescu, Eugeny Nasonov, Joung-Liang Lan, Lilia Pineda, Z John Zhong, William Freimuth, Michelle A Petri. Lancet 2011
Times Cited: 985







List of co-cited articles
695 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Richard Furie, Michelle Petri, Omid Zamani, Ricard Cervera, Daniel J Wallace, Dana Tegzová, Jorge Sanchez-Guerrero, Andreas Schwarting, Joan T Merrill, W Winn Chatham,[...]. Arthritis Rheum 2011
775
64

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
William Stohl, Andreas Schwarting, Masato Okada, Morton Scheinberg, Andrea Doria, Anne E Hammer, Christi Kleoudis, James Groark, Damon Bass, Norma Lynn Fox,[...]. Arthritis Rheumatol 2017
119
27

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.
Joan T Merrill, C Michael Neuwelt, Daniel J Wallace, Joseph C Shanahan, Kevin M Latinis, James C Oates, Tammy O Utset, Caroline Gordon, David A Isenberg, Hsin-Ju Hsieh,[...]. Arthritis Rheum 2010
716
24

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.
Brad H Rovin, Richard Furie, Kevin Latinis, R John Looney, Fernando C Fervenza, Jorge Sanchez-Guerrero, Romeo Maciuca, David Zhang, Jay P Garg, Paul Brunetta,[...]. Arthritis Rheum 2012
678
24

Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
Eric F Morand, Richard Furie, Yoshiya Tanaka, Ian N Bruce, Anca D Askanase, Christophe Richez, Sang-Cheol Bae, Philip Z Brohawn, Lilia Pineda, Anna Berglind,[...]. N Engl J Med 2020
193
23

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.
Antonis Fanouriakis, Myrto Kostopoulou, Alessia Alunno, Martin Aringer, Ingeborg Bajema, John N Boletis, Ricard Cervera, Andrea Doria, Caroline Gordon, Marcello Govoni,[...]. Ann Rheum Dis 2019
363
22

A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
Fengchun Zhang, Sang-Cheol Bae, Damon Bass, Myron Chu, Sally Egginton, David Gordon, David A Roth, Jie Zheng, Yoshiya Tanaka. Ann Rheum Dis 2018
64
32

Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.
Richard Furie, Brad H Rovin, Frédéric Houssiau, Ana Malvar, Y K Onno Teng, Gabriel Contreras, Zahir Amoura, Xueqing Yu, Chi-Chiu Mok, Mittermayer B Santiago,[...]. N Engl J Med 2020
69
30



Combined oral contraceptives in women with systemic lupus erythematosus.
Michelle Petri, Mimi Y Kim, Kenneth C Kalunian, Jennifer Grossman, Bevra H Hahn, Lisa R Sammaritano, Michael Lockshin, Joan T Merrill, H Michael Belmont, Anca D Askanase,[...]. N Engl J Med 2005
620
16


Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
Richard Furie, Munther Khamashta, Joan T Merrill, Victoria P Werth, Kenneth Kalunian, Philip Brohawn, Gabor G Illei, Jorn Drappa, Liangwei Wang, Stephen Yoo. Arthritis Rheumatol 2017
351
15

Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
M A Dooley, F Houssiau, C Aranow, D P D'Cruz, A Askanase, D A Roth, Z J Zhong, S Cooper, W W Freimuth, E M Ginzler. Lupus 2013
153
13

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.
Ronald F van Vollenhoven, Michelle A Petri, Ricard Cervera, David A Roth, Beulah N Ji, Christi S Kleoudis, Z John Zhong, William Freimuth. Ann Rheum Dis 2012
227
12


Novel evidence-based systemic lupus erythematosus responder index.
Richard A Furie, Michelle A Petri, Daniel J Wallace, Ellen M Ginzler, Joan T Merrill, William Stohl, W Winn Chatham, Vibeke Strand, Arthur Weinstein, Marc R Chevrier,[...]. Arthritis Rheum 2009
269
12

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.
Munther Khamashta, Joan T Merrill, Victoria P Werth, Richard Furie, Kenneth Kalunian, Gabor G Illei, Jorn Drappa, Liangwei Wang, Warren Greth. Ann Rheum Dis 2016
262
12

Systemic lupus erythematosus disease activity index 2000.
Dafna D Gladman, Dominique Ibañez, Murray B Urowitz. J Rheumatol 2002
12

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
Daniel J Wallace, Richard A Furie, Yoshiya Tanaka, Kenneth C Kalunian, Marta Mosca, Michelle A Petri, Thomas Dörner, Mario H Cardiel, Ian N Bruce, Elisa Gomez,[...]. Lancet 2018
169
12

BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus.
D A Isenberg, A Rahman, E Allen, V Farewell, M Akil, I N Bruce, D D'Cruz, B Griffiths, M Khamashta, P Maddison,[...]. Rheumatology (Oxford) 2005
303
11

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
Daniel J Wallace, William Stohl, Richard A Furie, Jeffrey R Lisse, James D McKay, Joan T Merrill, Michelle A Petri, Ellen M Ginzler, W Winn Chatham, W Joseph McCune,[...]. Arthritis Rheum 2009
352
10


Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.
Ronald F van Vollenhoven, Marta Mosca, George Bertsias, David Isenberg, Annegret Kuhn, Kirsten Lerstrøm, Martin Aringer, Hendrika Bootsma, Dimitrios Boumpas, Ian N Bruce,[...]. Ann Rheum Dis 2014
305
10

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.
Megan E B Clowse, Daniel J Wallace, Richard A Furie, Michelle A Petri, Marilyn C Pike, Piotr Leszczyński, C Michael Neuwelt, Kathryn Hobbs, Mauro Keiserman, Liliana Duca,[...]. Arthritis Rheumatol 2017
91
10

Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).
Kate Franklyn, Chak Sing Lau, Sandra V Navarra, Worawit Louthrenoo, Aisha Lateef, Laniyati Hamijoyo, C Singgih Wahono, Shun Le Chen, Ou Jin, Susan Morton,[...]. Ann Rheum Dis 2016
180
9

Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
Y K Onno Teng, Ian N Bruce, Betty Diamond, Richard A Furie, Ronald F van Vollenhoven, David Gordon, James Groark, Robert B Henderson, Mary Oldham, Paul P Tak. BMJ Open 2019
34
26

Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study.
Eduardo F Mysler, Alberto J Spindler, Renato Guzman, Marc Bijl, David Jayne, Richard A Furie, Frédéric A Houssiau, Jorn Drappa, David Close, Romeo Maciuca,[...]. Arthritis Rheum 2013
165
9

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study.
Daniel J Wallace, Kenneth Kalunian, Michelle A Petri, Vibeke Strand, Frederic A Houssiau, Marilyn Pike, Brian Kilgallen, Sabine Bongardt, Anna Barry, Lexy Kelley,[...]. Ann Rheum Dis 2014
177
9

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).
Kenneth C Kalunian, Joan T Merrill, Romeo Maciuca, Jacqueline M McBride, Michael J Townsend, Xiaohui Wei, John C Davis, William P Kennedy. Ann Rheum Dis 2016
202
9

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood.
Lynda Bennett, A Karolina Palucka, Edsel Arce, Victoria Cantrell, Josef Borvak, Jacques Banchereau, Virginia Pascual. J Exp Med 2003
9

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
Michelle Petri, William Stohl, Winn Chatham, W Joseph McCune, Marc Chevrier, Jeff Ryel, Virginia Recta, John Zhong, William Freimuth. Arthritis Rheum 2008
254
9


Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples.
Venkat Reddy, Christian Klein, David A Isenberg, Martin J Glennie, Geraldine Cambridge, Mark S Cragg, Maria J Leandro. Rheumatology (Oxford) 2017
48
18

Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.
C Bombardier, D D Gladman, M B Urowitz, D Caron, C H Chang. Arthritis Rheum 1992
9

Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.
Richard A Furie, Daniel J Wallace, Cynthia Aranow, James Fettiplace, Barbara Wilson, Prafull Mistry, David A Roth, David Gordon. Arthritis Rheumatol 2018
30
30

2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.
Antonis Fanouriakis, Myrto Kostopoulou, Kim Cheema, Hans-Joachim Anders, Martin Aringer, Ingeborg Bajema, John Boletis, Eleni Frangou, Frederic A Houssiau, Jane Hollis,[...]. Ann Rheum Dis 2020
79
11

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.
Michelle Petri, Ana-Maria Orbai, Graciela S Alarcón, Caroline Gordon, Joan T Merrill, Paul R Fortin, Ian N Bruce, David Isenberg, Daniel J Wallace, Ola Nived,[...]. Arthritis Rheum 2012
9

Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort.
Ian N Bruce, Aidan G O'Keeffe, Vern Farewell, John G Hanly, Susan Manzi, Li Su, Dafna D Gladman, Sang-Cheol Bae, Jorge Sanchez-Guerrero, Juanita Romero-Diaz,[...]. Ann Rheum Dis 2015
215
8

The BAFF/APRIL system in SLE pathogenesis.
Fabien B Vincent, Eric F Morand, Pascal Schneider, Fabienne Mackay. Nat Rev Rheumatol 2014
211
8

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.
Richard Furie, William Stohl, Ellen M Ginzler, Michael Becker, Nilamadhab Mishra, Winn Chatham, Joan T Merrill, Arthur Weinstein, W Joseph McCune, John Zhong,[...]. Arthritis Res Ther 2008
165
8

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus.
Emily C Baechler, Franak M Batliwalla, George Karypis, Patrick M Gaffney, Ward A Ortmann, Karl J Espe, Katherine B Shark, William J Grande, Karis M Hughes, Vivek Kapur,[...]. Proc Natl Acad Sci U S A 2003
8

B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.
William Stohl, Samy Metyas, Soon-Min Tan, Gurtej S Cheema, Bonifacia Oamar, Dong Xu, Viktor Roschke, Youmei Wu, Kevin P Baker, David M Hilbert. Arthritis Rheum 2003
357
8


Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis.
Yemil Atisha-Fregoso, Susan Malkiel, Kristina M Harris, Margie Byron, Linna Ding, Sai Kanaparthi, William T Barry, Wendy Gao, Kristin Ryker, Patti Tosta,[...]. Arthritis Rheumatol 2021
17
47

Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care.
I N Bruce, M Urowitz, R van Vollenhoven, C Aranow, J Fettiplace, M Oldham, B Wilson, C Molta, D Roth, D Gordon. Lupus 2016
48
14

Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations.
F Mackay, S A Woodcock, P Lawton, C Ambrose, M Baetscher, P Schneider, J Tschopp, J L Browning. J Exp Med 1999
7


The 1982 revised criteria for the classification of systemic lupus erythematosus.
E M Tan, A S Cohen, J F Fries, A T Masi, D J McShane, N F Rothfield, J G Schaller, N Talal, R J Winchester. Arthritis Rheum 1982
7

The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus.
D Gladman, E Ginzler, C Goldsmith, P Fortin, M Liang, M Urowitz, P Bacon, S Bombardieri, J Hanly, E Hay,[...]. Arthritis Rheum 1996
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.